Gan & Lee’s Once-Weekly Insulin GZR4 Meets Primary Endpoints in Phase 3 Trials

Key Facts

1Gan & Lee Pharmaceuticals announced that its once-weekly insulin GZR4 injection met primary endpoints in two pivotal Phase 3 clinical trials, SUPER-1 and SUPER-2.

2The SUPER-1 and SUPER-2 trials are pivotal for evaluating the efficacy and safety of the investigative basal insulin GZR4.

3The company's shares are traded on the Shanghai Stock Exchange under the ticker 603087.

Gan & Lee Pharmaceuticals (SSE: 603087) announced that its investigative once-weekly basal insulin injection, GZR4, successfully met primary endpoints in two pivotal Phase 3 clinical trials. The trials, named SUPER-1 and SUPER-2, were designed to evaluate the efficacy and safety of the long-acting insulin compared to daily alternatives. Achieving these milestones marks a significant step toward regulatory approval and commercialization for the biotech firm. By reducing injection frequency from daily to weekly, GZR4 aims to significantly improve patient compliance and quality of life for those managing diabetes. The positive clinical data is expected to bolster investor confidence in the company's research and development pipeline. This development positions Gan & Lee as a strong competitor in the global diabetes treatment market.